Main Street Research LLC Buys 103 Shares of Eli Lilly and Company (NYSE:LLY)

Main Street Research LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,132 shares of the company’s stock after buying an additional 103 shares during the period. Main Street Research LLC’s holdings in Eli Lilly and Company were worth $1,826,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the third quarter worth about $27,000. Retirement Group LLC lifted its holdings in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $33,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Finally, Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley lifted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Barclays boosted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $1.57 during trading on Tuesday, reaching $749.20. 1,363,776 shares of the company’s stock were exchanged, compared to its average volume of 3,068,220. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $711.86 billion, a PE ratio of 128.34, a PEG ratio of 1.65 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The firm’s fifty day moving average price is $762.68 and its 200-day moving average price is $655.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the firm posted $2.09 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.46 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.